Metronomic low-dose chemotherapy has a broad, mainly anti-angiogenic profile and showed to some degree monoactivity in advanced HCC, whereas COX-2 inhibitors and PPARγ agonists showed antitumoral activity only in the adjuvant setting [11, 12]. Here, PPARG is linked to hepatocellular carcinoma.